Lorbrexen-100-lorlatinib

Name: Lorbrexen-100-lorlatinib
Brand: Meds For Cancer
SKU: 1992
Price: 980 USD
Availability: InStock

Lorbrexen-100-lorlatinib is a non-small-lung cancer medicine that has huge potential against most known resistance mutations that can develop during treatment with crizotinib and second-generation ALK TKIs.

Lorbrexen, manufactured by Everest Pharmaceuticals Ltd in Bangladesh, is equally effective as Loraltinib.

Lorbrexen-100-lorlatinib Indication:

Lorlatinib is prescribed to adult patients who have Anaplastic Lymphoma Kinase metastatic non-small cell lung cancer. (1) It is also recommended for those who haveadvanced NSCLC and have not previously received ALK inhibitor treatment, and those whose disease has not been cured after using Alectinib, Ceritinib, or Crizotinib.

Lorbrexen-100-lorlatinib Mechanism of Action

Lorlatinib is a third-generation anaplastic lymphoma kinase (ALK) inhibitor, used to treat non-small cell lung cancer (NSCLC) with ALK mutations, including those that have become resistant to other ALK inhibitors. It is also used to treat ROS1-positive NSCLC.

Lorlatinib works by blocking the ALK and ROS1 proteins. These proteins are involved in the growth and survival of cancer cells. By blocking these proteins, lorlatinib can help slow or stop cancer cell growth.

Lorlatinib is a reversible inhibitor, which means that it can bind to and unbind from the ALK and ROS1 proteins. This allows lorlatinib to be more effective against tumors that have developed resistance to other ALK inhibitors.

Here is a simplified explanation of how lorlatinib works:

ALK and ROS1 proteins are located on the surface of cancer cells.
Lorlatinib binds to the ALK and ROS1 proteins, blocking their activity.
Without the activity of ALK and ROS1 proteins, cancer cells cannot grow and survive.
As a result, cancer cells die or stop growing. (2)

Lorbrexen-100-lorlatinib Dosage and Absorption:

After being taken orally, Lorlatinib is quickly absorbed and reaches its peak concentration in the bloodstream within 1-2 hours. It has high bioavailability, meaning that a significant amount of the drug is absorbed into the bloodstream.

Dosage:

The recommended daily dosage of Lorlatinib is 100 mg, which can be taken with or without food. However, if a patient has difficulty tolerating this amount, a reduced dosage of either 75 mg or 50 mg can be administered.

It’s important to avoid taking Lorlatinib with strong CYP3A inhibitors such as ketoconazole, itraconazole, or posaconazole, which can increase blood levels and cause side effects. Additionally, caution should be used when administering the drug to patients with liver or kidney problems, as they may require a lower dosage.

It’s essential to understand that the dosage and administration of Lorlatinib vary depending on individual patient needs and medical history. Therefore, it’s crucial to consult with a doctor to determine the appropriate dosage for each patient. (3)

Side Effects:

The most common side effects of lorlatinib are mild and go away on their own. These side effects may include:

Less common side effects of lorlatinib include:

Liver problems
Lung problems
Heart problems
Nerve problems
Blood problems

Serious side effects of lorlatinib are rare. However, it is important to be aware of the potential side effects of lorlatinib so that you can talk to your doctor if you experience any of them.

If you are taking lorlatinib, be sure to tell your doctor about any other medications you are taking, including over-the-counter medications, herbal supplements, and vitamins. Some medications can interact with lorlatinib and cause side effects.

You should also tell your doctor about any medical conditions you have, including liver problems, kidney problems, heart problems, and nerve problems. Lorlatinib may not be safe for everyone to take. (4)

Lorlatinib Survival Rate:

The median progression-free survival (PFS) was 9.9 months (with a 95% confidence interval of 6 to 12.3 months) from when lorlatinib was first given. The median overall survival (OS) from the start of lorlatinib treatment was 32.9 months (with a 95% confidence interval of 18.7 months to not reached). The median OS from the time of advanced non-small cell lung cancer (NSCLC) diagnosis was 97.3 months (with a 95% confidence interval of 75.7 to 152.8 months). (5)

ROS-1 Lorlatinib:

Lorlatinib is a targeted therapy medication that is specifically designed to treat non-small cell lung cancer (NSCLC) in individuals who are ROS-1 positive. ROS-1 is a protein that plays a crucial role in the growth and survival of cancer cells, and lorlatinib works by blocking this protein. This can help to reduce tumor size and increase survival rates.

Although lorlatinib is a relatively new drug, it has already become a first-line treatment for those with ROS-1-positive NSCLC. It is also used to treat patients who have not responded well to other treatments for this type of cancer.

Overall, lorlatinib is generally well-tolerated, with mild side effects such as nausea, vomiting, diarrhea, fatigue, and decreased appetite. However, more serious side effects such as liver problems, lung problems, and heart problems are rare.

If you are considering lorlatinib as a treatment option for your ROS-1-positive NSCLC, it is important to discuss the potential risks and benefits with your doctor. While lorlatinib can be an effective treatment, it is crucial to be aware of the potential side effects. (6)

Comparison Among ALECTINIB vs LORALTINB vs CRIZOTINIB

Alectinib, lorlatinib, and crizotinib are all targeted therapy medications used to treat non-small cell lung cancer (NSCLC) with ALK mutations. They work by blocking the ALK protein, which is involved in the growth and survival of cancer cells.

Here is a comparison of the three medications:

Feature	Alectinib	Lorlatinib	Crizotinib
Generation	Second-generation ALK inhibitor	Third-generation ALK inhibitor	First-generation ALK inhibitor
Approval	2015	2018	2011
Efficacy	Highly effective against ALK-positive NSCLC, including tumors that have become resistant to crizotinib	Very effective against ALK-positive NSCLC, including tumors that have become resistant to other ALK inhibitors	Effective against ALK-positive NSCLC, but not as effective as alectinib or lorlatinib
Side effects	Generally well-tolerated, with mild to moderate side effects	Generally well-tolerated, with mild to moderate side effects	More common and severe side effects than alectinib or lorlatinib
Cost	Expensive	Expensive	Less expensive than alectinib or lorlatinib

Overall, lorlatinib is the most effective and well-tolerated of the three medications. It is also the most expensive. Alectinib is also a very effective medication, but it can cause more side effects than lorlatinib. Crizotinib is the least effective of the three medications, and it can also cause more side effects than alectinib or lorlatinib.

The best medication for you will depend on your individual needs and medical history. If you have ALK-positive NSCLC, talk to your doctor about the risks and benefits of each medication to decide which one is right for you. (7)

What is Lorbrexen-100-lorlatinib?

Lorbrexen is a very effective, highly potent, brain-penetrant, third-generation ALK tyrosine kinase inhibitor. Which works against non-small-cell lung cancer and has a vast record of good results. Lorbrexen works by stopping the mutation and rapid growth of cancer cells in the human body. That helps patients with non-small-cell lung cancer get recover from cancer.

How to use Lorbrexen-100-lorlatinib?

Lorbrexen is an oral medicine that comes as tablets. Pharmacists and doctors suggest their patients to swallow Lorbrexen tablets with or without food, before or after taking the meal, once or twice a day.

How to place an order for Lorbrexen-100-lorlatinib?

One can place his/her order via Whats app, WeChat, and other available ways that are given on the contact us page. or directly send Wahats app message to this number +8801304498958

What are the side effects of Lorbrexen-100-lorlatinib?

There are a few common side effects of using Lorbrexen like muscle pain, joint pain, diarrhea, constipation, vomiting, and tiredness.

Is Loraltinib approved by FDA?

In first week of the march 2021 FDA approved Loraltinib for those patients with non-small-lung cancer whose tumors are Anaplastic Lymphoma kinase postive.

What is the cost of Lorbrexen-100-lorlatinib?

The cost for Lorbrexen-100-lorlatinib oral tablet 25 mg is around $7,082 for a supply of 30 tablets, depending on the pharmacy you visit. But We provide this medicine at a lower cost comparing to the global market. You can make your purchase by placing your order.